Close

GSK invests $120 million in biopharma plant as its oncology pipeline grows

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Pharmacy’s Impact on Reducing Medication Errors in Hospital Settings

Medication errors are a big problem in healthcare because...

How to Dispose of Pharmaceutical Waste

Proper pharmaceutical waste disposal is crucial for protecting our...

Semaglutide 101: What You Need to Know About This Game-Changing Medication

In the realm of modern medicine, breakthroughs are not...

Health Benefits of Pre-work Supplements

Whether you are a workout expert or just starting...

Amidst a pipeline bulging with oncology bets, GlaxoSmithKline has invested $120 million in a new biologics plant. The announcement was made by Emma Walmsley, CEO, at the drugmaker’s manufacturing site at Upper Merion, Pennsylvania. According to her, the investment will support and accelerate the transformation of GSK’s pipeline to deliver the next generation of medicines and vaccines.

GSK has invested almost $400 million in vaccines and specialty drugs across its US manufacturing network. The company has also put in place a deal to make its chickenpox vaccine in Russia. This comes at a time when GSK is pushing its vaccine portfolio abroad.

Latest stories